STOCK TITAN
  1. Home
  2. News
  3. BHC

Bausch Health Companies Inc - BHC STOCK NEWS

Welcome to our dedicated news page for Bausch Health Companies (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bausch Health Companies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bausch Health Companies's position in the market.

News
Salix Announces 2024 Gastrointestinal Health Scholars Program
Rhea-AI Summary
Bausch Health Companies Inc. announces the 2024 Salix Gastrointestinal Health Scholars Program, offering scholarships of up to $10,000 to 10 students living with GI diseases. Application period closes on May 6, 2024, with recipients notified in the summer of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
-
News
Bausch Health Announces Board Refreshment
Rhea-AI Summary
Bausch Health Companies Inc. announced the nomination of two independent and diverse candidates to stand for election to its Board of Directors at the Company's 2024 Annual Meeting of Shareholders. Christian A. Garcia, Former Executive Vice President and CFO of BrandSafway Industries, LLC, and Frank D. Lee, CEO of Pacira Biosciences, Inc., are the nominees. In addition, Russel C. Robertson and Thomas W. Ross, Sr. will be retiring from the Board and will not stand for re-election at the Company's 2024 Annual Meeting. The Company expects Mr. Garcia to serve as the Audit and Risk Committee chair and Mr. Lee to serve on the Talent and Compensation Committee. The 2024 Annual Meeting has not yet been scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
News
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
Rhea-AI Summary
Bausch Health Companies Inc. (BHC) will release its Q4 and full-year 2023 financial results on Feb. 22, 2024. A conference call and webcast will follow to discuss the results and provide a business update. The materials will be available on the Investor Relations section of the Bausch Health website. The live Q&A session will require registration to receive a PIN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
earnings
News
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
Rhea-AI Summary
Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, have announced the U.S. launch of CABTREO, a topical gel for the treatment of acne vulgaris. The gel is the first FDA-approved fixed-dose, once-daily triple-combination topical treatment for acne, offering three mechanisms of action. It has shown statistically significant reductions in both inflammatory and non-inflammatory lesions compared to a vehicle gel, with 50.0% of participants achieving treatment success with CABTREO versus 22.6% with the vehicle gel at week 12. However, the gel has also shown some common adverse reactions, including application site reactions, pain, erythema, dryness, irritation, exfoliation, and dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
News
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Rhea-AI Summary
Bausch Health Companies Inc. and Solta Medical announced the approval of Thermage FLX and the TR-4 Return Pad by China's National Medical Products Administration. This is a significant milestone for Solta Medical and represents a major breakthrough in one of the largest medical aesthetics markets. The approval allows the companies to continue the growth of Thermage in China, a non-invasive treatment that uses radiofrequency technology to tighten and improve the skin's surface. The approval is expected to drive business growth and expand the reach of Thermage FLX proven technology to the Chinese market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
News
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Rhea-AI Summary
Bausch Health Companies Inc. and Solta Medical announced the approval of Thermage FLX and the TR-4 Return Pad by China's NMPA. The approval is significant for Solta Medical and represents an important breakthrough in the medical aesthetics market. The approval allows the companies to continue the momentum of the growth of Thermage in China, which has been serving Chinese institutions and consumers effectively since 2015. Thermage is a non-invasive treatment that uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin's surface. It is a versatile and effective treatment that can be used on all skin types and genders, on a wide range of areas on the face, body, and around the eyes. Globally, more than two million Thermage treatments have been performed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
News
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
Rhea-AI Summary
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and Salix Pharmaceuticals, a subsidiary, announced oral arguments at the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. No ruling was issued, and the company looks forward to the Court's decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
News
Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
Rhea-AI Summary
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) announced positive topline results from the Phase 2 study of Amiselimod for the treatment of ulcerative colitis. The study met both primary and key secondary endpoints, with impressive efficacy results and a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
clinical trial
-
News
DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
Rhea-AI Summary
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) announced that DUOBRII, a novel topical prescription drug for plaque psoriasis, is now available to patients enrolled in Quebec's public drug plan. The drug is already available on most other public drug plans in Canada and the NIHB program. Manufactured in Quebec, it has been available by prescription since August 2020.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
News
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
Rhea-AI Summary
Salix Pharmaceuticals (BHC) partners with USPF and IFFGD to declare Opioid-Induced Constipation (OIC) Awareness Day
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
none
Stock BHC logo
Bausch Health Companies Inc

NYSE:BHC

BHC Rankings

#1504 Ranked by Market Cap
#1934 Ranked by Stock Gains
N/A Ranked by Dividends

BHC Stock Data

3.21B
303.99M
0.91%
79.62%
6.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
CA
Laval

About BHC

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###